Clinical trial success is a delicate balance of research, relationships and results. At Metroplex Clinical Research Center, we've found the formula.

• 23 Years of Experience
• A Track Record of Achievement
• A Team of Top Doctors
• State-of-the-Art Research Facilities

Areas of experience include:

• Rheumatology
• Rheumatoid arthritis
• Osteoarthritis
• Osteoporosis
• Lupus
• Cardiovascular disease
• Hypercholesterolemia
• Hypertension
• Sleep disorders
• Smoking cessation
• Obesity
• Dermatology
• Psoriasis
• Migraine
• Vaccine
• HIV Vaccine
• Flu Vaccine

MCRC staff includes board certified rheumatologists, experienced coordinators, recruitment specialists, regulatory specialists, and laboratory technicians.

Comprehensive services include:

• Ten physician investigators
• Three physician extenders, two nurse practitioners and one physician's assistant
• Full-service X-ray department including bone density testing
• Onsite CLIA-certified laboratory
• Onsite infusion unit

Roy M. Fleischmann, M.D.
Medical Director

Dr. Fleischmann is a clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center (UTSMC) and is in private practice at Rheumatology Associates in Dallas. He has served as chief of the Division of Rheumatology at UTSMC University Hospitals’ St. Paul, Dallas, since 1978. Dr. Fleischmann has been the co-medical director of Radiant Research in Dallas, since 1999.

He received his Doctor of Medicine (M.D.) from State University of New York, Downstate Medical Center, in 1969, before completing his residency in internal medicine at the Mt. Sinai Hospital, New York City, and his fellowship in rheumatology at the College of Physicians and Surgeons, Columbia University, New York City.

He is a diplomate of the American Board of Internal Medicine and is a fellow of the American College of Rheumatology. He has served on the finance committee of the American College of Rheumatology and the fund-raising committee of the Research and Education Foundation (REF) of the American College of Rheumatology. He has previously served on the board of directors and the executive committee of the North Texas Arthritis Foundation. He has been president of the Texas Rheumatism Society and has sat on the governing board of the Texas Rheumatism Association. He has been a consultant to pharmacological companies in the areas of trial design, protocol development and CME development. He is a member of the Inflammation Research Association, the Associates of Clinical Pharmacology and the Drug Information Association. He has been involved in many clinical trials on treatments for osteoarthritis and rheumatoid arthritis and has published more than 60 peer-reviewed articles in these areas. Dr. Fleischmann has been voted one of the Best Doctors in Dallas as well as Texas Super Doctors.

Stanley B. Cohen, M.D.
Medical Director

Dr. Cohen is a clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School (UTSMS) and is in private practice at Rheumatology Associates in Dallas. He is associate director of the Division of Rheumatology at UTSMC University Hospitals’ St. Paul and medical director of Metroplex Clinical Research Center in Dallas. Dr. Cohen is actively involved in teaching rheumatology fellows and residents during their clinical rotations in the office.

Dr. Cohen graduated Phi Beta Kappa with a degree in biology from the University of Virginia and received his Doctor of Medicine (M.D.) with honors from the University of Alabama School of Medicine in Birmingham, where he was inducted into Alpha Omega Alpha Honor Medical Society. He then completed an internship and residency in internal medicine at Parkland Memorial Hospital in Dallas and a fellowship in rheumatology at St. Paul Medical Center/Southwestern Medical School in Dallas. Dr. Cohen is board certified in internal medicine with sub-specialty certification in rheumatology.

A fellow of the American College of Rheumatology, Dr. Cohen was past-chairman of the board of the North Texas Arthritis Foundation (AF) and was honored with the AF Medical Profession Award in 1994. He was president of the American College of Rheumatology Research and Education Foundation from 2000 to 2002 and served on the board of directors of the American College of Rheumatology from 2001 to 2004. He was previously on the Medical Advisory Board of Directors of the Harold C. Simmons Arthritis Center at the University of Texas Southwestern Medical School. Dr. Cohen is presently secretary treasurer of the American College of Rheumatology and a member of the University of Texas Southwestern Medical School CME Executive Committee.

He has served as a consultant to the pharmaceutical industry on protocol development in rheumatoid arthritis, glucocorticoid induced osteoporosis and disease modification in osteoarthritis, as well as medical advisory boards and data safety monitoring committees. Dr. Cohen has been an author or co-author of book chapters, articles and abstracts that have been published in many leading journals and presented at national and international medical and scientific symposia. He also received the Howard. C. Coggeshall Lifetime Achievement Service Award from the North Texas Arthritis Foundation in 2006 for longtime support of the Foundation and its programs.

The center employs certified and trained coordinators, recruitment specialists, regulatory specialists and laboratory technicians as well as a distinguished contingent of nine board certified rheumatologists. Medical directors Roy M. Fleischmann, M.D., and Stanley B. Cohen, M.D., have 50 years of combined clinical research experience and, between them, have published 100 scientific papers and co-authored four medical books. They are lecturers on the subjects of research and treatment of arthritis and osteoporosis and serve as advisors to major pharmaceutical companies.

The MCRC database contains names of more than 3,000 healthy subjects and more than 20,000 individuals who have participated in clinical research studies or expressed an interest in participation.

Since its founding in 1984 as a multi-specialty clinical research site, Metroplex Clinical Research Center (MCRC) has completed more than 800 Phase I-IV clinical studies in a variety of therapeutic areas, including rheumatology, osteoporosis and musculoskeletal pain. Headquartered on the campus of St. Paul Medical Center at the University of Texas Southwestern in Dallas, MCRC boasts four satellite offices serving a patient population of 1 million.

CenterWatch is listing the following trials that are actively recruiting patients at this center.

• A Multicenter, Randomized, Double-Period, Double-Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early Rheumatoid Arthritis
• A Phase 3, 53 Weeks Study on Analgesic Efficacy and Safely of Naproxcinod (HCT 3012): 26-Week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks)- and Naproxen (26 Weeks)-Controlled, Multicenter Study of Naproxcinod (375 mg bid and 750 mg bicf) with a 26-Week Naproxen-Controlled Safety Follow-up in Subjects with Osteoarthritis of the Knee, and a 1-Week Post-treatment Safely Follow-up
• A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with ISN/RPS Class III or IV Lupus Nephritis
• A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen
• A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF therapy.
• Efficacy and safety of 2 mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus: a 12 week, multi-center, randomized, double-blinded, placebo-controlled study
• Osteoarthritis of the knee

For more information, please contact:

Sara Hibbard
Site Director
Metroplex Clinical Research Center
5939 Harry Hines Blvd. Ste. 441
Dallas, TX 75235 USA
Phone: 214-879-6737
Fax: 214-879-8794
E-mail:

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.

Name:
Address:
City:
State:
Zip:
Phone:
Email address:
Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

Last updated on August 21, 2008